Cell and Gene Outsourcing

  1. Innovating Upstream Manufacturing For The Next Wave Of Gene Therapies 3/4/2026

    Explore a streamlined approach to transient AAV production, including yield improvements across serotypes, key transfection parameters, and practical guidance for scaling processes.

  2. How Molecular Structure Influences Potency Of A Therapeutic Biologic 7/17/2019

    Gain an understanding of how an antibody’s molecular structure and its many measurable properties influences its binding and affects potency of a therapeutic biologic.

  3. Identify And Quantify AAV Fill States Using Analytical Ultracentrifugation 3/14/2024

    Explore how to implement analysis using sedimentation velocity analytical ultracentrifugation to characterize AAV size distributions and multiple detection wavelengths to identify various fill states in AAV preparation.

  4. Biotherapy Characterization: Cell-Based Assays 7/17/2019

    MilliporeSigma Senior Scientist Agata Burzawa, MSc, explains how we can provide you with rich data sets to help you understand your complex biotherapy faster. Using limited volumes of samples for testing, our scientists employ leading technologies that integrate cytokine release monitoring with immunophenotyping of cells within the same sample.

  5. The Journey To Safety Through Viral Clearance 12/1/2022

    Discover a simple yet powerful solution for getting viral clearance studies done safely, thoroughly, efficiently, and on your timelines. Learn how to free your teams and trust your project.

  6. Eliminate Risk From Your Viral Vector Tech Transfers 12/5/2025

    Explore strategies to simplify viral vector tech transfers, reduce risk, and maintain quality under tight timelines, as well as a case study that demonstrates how to streamline this critical process.

  7. Navigating The Complex Landscape Of Lentiviral Vector Quality Control 6/26/2025

    Explore the latest in lentiviral vector release testing, which covers biosafety, regulatory insights, and QC strategies to ensure patient safety and accelerate your path to clinic.

  8. Process Impurities: Don't Let PEI Or HCP Derail Your Biotherapy

    Learn product characterization strategies to de-risk manufacturing and detect and characterize host cell proteins and polyethylenimine in mAb and cell and gene therapies.

  9. Selecting The Right CMO For Your Gene Therapy 5/15/2020

    Find out what criteria makes a great CMO partner and how to know if it is the right one for your gene therapy.

  10. Biotherapy Characterization: Binding Assays 7/17/2019

    MilliporeSigma Senior Scientist Helen Hsu, Ph.D. describes how, with our custom binding assays, and supported with our comprehensive off-the-shelf Fc gamma receptor binding assays, we can help you optimize your mAb production, from clone development through upstream and downstream processes.